Milnacipran: A Dual Norepinephrine and Serotonin Reuptake Pump Inhibitor

Journal of Psychiatric Practice

Volumn 10, Issue 2, 2004, Pages 119-126

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; CHLORAMPHETAMINE; CLOMIPRAMINE; CLONIDINE; CLORGYLINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIPRAMINE; LITHIUM; MILNACIPRAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TRYPTOPHAN; VERAPAMIL; YOHIMBINE;

ANXIETY; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSURIA; HEADACHE; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; LONG TERM CARE; META ANALYSIS; NAUSEA; NONHUMAN; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; XEROSTOMIA;

ANIMALS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFUSION PUMPS, IMPLANTABLE; NOREPINEPHRINE; RATS; SEROTONIN UPTAKE INHIBITORS;

EID: 1642423852     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200403000-00006     Document Type: Review

References (52)

1. Preskorn SH. Reboxetine: A norepinephrine selective reuptake pump inhibitor. Journal of Psychiatric Practice 2004;10:57-63.
2. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. Journal of Psychiatric Practice 2003;9:376-84.
3. Preskorn SH. Modern drug development and the Human Genome Project. Series of columns published in the Journal of Psychiatric Practice between 2000 and 2002 (www.preskorn.com/column4.html)
4. Preskorn SH. The polypharmacology section. Series of columns published in the Journal of Psychiatric Practice between 1997 and 2003 (www.preskorn.com/column1.html)
5. Tajima O. Japanese experience with dual-action antidepressants. Int Clin Psychopharmacol 2002;17:S37-S42.
6. Preskorn SH. Two in one: The venlafaxine story. Journal of Practical Psychiatry and Behavioral Health 1999;5:346-50 (www.preskorn.com/column2.html).
7. Deprez D, Chassard D, Baille P, et al. Which bioequivalence study for a racemic drug? Application to milnacipran. Eur J Drug Metab Pharmacokinet 1998;23:166-71.
8. Puozzo C, Pozet N, Deprez D, et al. Pharmacokinetics of milnacipran in renal impairment. Eur J Drug Metab Pharmacokinet 1998:23:280-6.
9. Grard S, Morin P, Dreux M, et al. Enhancement of second-migrating enantiomer peak symmetry of basic drugs by using dual-cyclodextrin system in capillary electrophoresis. Electrophoresis 2000;21:3028-32.
10. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996;11:9-14.
11. Delini-Stula A. Milnacipran: An antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Hum Psychopharmacol 2000;15:255-60.
12. Barone P, Moret C, Briley M, et al. Autoradiographic characterization of binding sites for [3H] milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain. Brain Res 1994;30:129-43.
13. Moret C, Briley M. Effect of milnacipran and desipramine on noradrenergic alpha 2-autoreceptor sensitivity. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:1063-72.
14. Bel N, Artigas F. Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran: Microdialysis studies in rats. Neuropsychopharmacology 1999;21:745-54.
15. Mongeau R, Weiss M, de Montigny C, et al. Effect of acute, short and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology 1998;37:905-18.
16. Maj J, Rogoz Z, Dlaboga D, et al. Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the alpha 1-adrenergic and serotonergic 5-HT2A systems. J Neural Transm 2000;107:1345-59.
17. Reneric JP, Bouvard M, Stinus L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 2002;136:521-32.
18. Assie MB, Charveron M, Palmier C, et al. Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 1992;31:149-55.
19. Neliat G, Bodinier MC, Panconi E, et al. Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the beta-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology 1996;35:589-93
20. Moret C, Briley M. Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol 1990;180:351-6.
21. Mochizuki D, Hokonohara T, Kawasaki K, et al. Repeated administration of milnacipran induces rapid desensitization of somatodendritic 5-HT1A auto receptors but not postsynaptic 5-HTIA receptors. J Psychopharmacol 2002;16:253-60.
22. Rogoz Z, Margas W, Dlaboga D, et al. Effect of repeated treatment with milnacipran on the central dopaminergic system. Pol J Pharmacol 2000;52:83-92.
23. Mochizuki D, Tsujita R, Yamada S, et al. Neurochemical and behavioural characterization of milnacipran a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology 2002;162:323-32.
24. Stenger A, Couzinier JP, Briley M. Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-amino-methylcyclopropane hydrochloride (F2207), a new potential antidepressant. Psychopharmacology 1987;91:147-53.
25. Okuyama-Tamura M, Mikuni M, et al. Modulation of the human glucocorticoid receptor function by antidepressive compounds. Neurosci Lett 2003;342:206-10.
26. Palmier C, Puozzo C, Lenehan T, et al. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. Eur J Clin Pharmacol 1989;37:235-8.
27. Rouet RH, Tisne-Versailles J, Adamantidis MM, et al. Comparative in vivo and in vitro study of the cardiac effects of midalcipran and imipramine. Fundam Clin Pharmacol 1989;3:237-44.
28. Caron J, Libersa C, Hazard JR, et al. Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 1993;3:493-500.
29. Puozzo C, Albin H, Vincon G, et al. Pharmacokinetics of milnacipran in liver impairment. Eur J Drug Metab Pharmacokinet 1998;23:273-9.
30. Hindmarch I, Rigney U, Stanley N, et al. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 2000;49:118-25.
31. Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108.
32. Montgomery SA, Prost JF, Solles A, et al. Efficacy and tolerability of milnacipran: An overview. Int Clin Psychopharmacol 1996;11:47-51.
33. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996;11(Suppl 4):41-6.
34. Preskorn SH. Finding the signal through the noise: The use of surrogate markers. Journal of Practical Psychiatry and Behavioral Health 1999;5:104-9.
35. Spencer CM, Wilde MI. Milnacipran. A review of its use in depression. Drugs 1998;56:405-27.
36. Yoshida K, Higuchi H, Takahashi H, et al. Elevation of blood pressure induced by high-dose milnacipran. Hum Psychopharmacol 2002;17:431.
37. Lecrubier Y, Pletan Y, Solles A, et al. Clinical efficacy of milnacipran: Placebo-controlled trials. International Clinical Psychopharmacology 1996;11(suppl 4):29-33.
38. Macher JP, Sichel JP, Serre C, et al. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989;22:77-82.
39. Kasper S, Pletan Y, Solles A, et al. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial results. International Clinical Psychopharmacology 1996;11(Suppl 4):35-9.
40. Van Ameringen M, Ferrey G, Tournoux A. A randomized double-blind comparison of milnacipran and imipramine in the treatment of depression. J Affect Disord 2002;72:21-31.
41. Ansseau M, von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacol 1989;98:163-8.
42. Tignol J, Pujol-Domenech J, Chartres JP, et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 1998;97:157-65.
43. Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 1994;114:131-7.
44. Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine. Int Clin Psychopharmacol 2001;16:145-51.
45. Fukuchi T, Kanemoto K. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: A case-control study. Int Clin Psychopharmacol 2002;17:53-8.
46. Steen A, Den Boer JA. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Psychopharmacol 1997;12:269-81.
47. von Frenckell R, Ansseau M, Serre C, et al. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. Int Clin Psychopharmacol 1990;5:49-56.
48. Ansseau M, von Frenckell R, Gerard MA, et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients: Comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol 1991;1:113-21.
49. Higuchi H, Yoshida K, Takahashi H, et al. Remarkable effect of milnacipran in the treatment of Japanese depressive patients. Hum Psychopharmacol 2002;17:195-6.
50. Yoshida K, Higuchi H, Takahashi H, et al. Favorable effect of milnacipran on depression induced by interferon-alpha. J Neuropsychiatry Clin Neurosci 2003;15:242-3.
51. Rouillon F, Berdeax G, Bisserbe JC, et al. Prevention of recurrent episodes with milnacipran: Consequences on quality of life. J Affect Disord 2000;58:171-80.
52. Leinonen E, Lepola U, Koponen H, et al. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 1997;96:497-504.